These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pembrolizumab as first-line treatment for metastatic uveal melanoma. Rossi E; Pagliara MM; Orteschi D; Dosa T; Sammarco MG; Caputo CG; Petrone G; Rindi G; Zollino M; Blasi MA; Cassano A; Bria E; Tortora G; Schinzari G Cancer Immunol Immunother; 2019 Jul; 68(7):1179-1185. PubMed ID: 31175402 [TBL] [Abstract][Full Text] [Related]
5. The Role of Immune Checkpoint Blockade in Uveal Melanoma. Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269 [TBL] [Abstract][Full Text] [Related]
6. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone. Afzal MZ; Mabaera R; Shirai K J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557 [TBL] [Abstract][Full Text] [Related]
11. Six-gene-based prognostic model predicts overall survival in patients with uveal melanoma. Wan Q; Tang J; Lu J; Jin L; Su Y; Wang S; Cheng Y; Liu Y; Li C; Wang Z Cancer Biomark; 2020; 27(3):343-356. PubMed ID: 31903983 [TBL] [Abstract][Full Text] [Related]
12. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. Piperno-Neumann S; Larkin J; Carvajal RD; Luke JJ; Schwartz GK; Hodi FS; Sablin MP; Shoushtari AN; Szpakowski S; Chowdhury NR; Brannon AR; Ramkumar T; de Koning L; Derti A; Emery C; Yerramilli-Rao P; Kapiteijn E Mol Cancer Ther; 2020 Apr; 19(4):1031-1039. PubMed ID: 32029634 [TBL] [Abstract][Full Text] [Related]
13. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma. Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109 [TBL] [Abstract][Full Text] [Related]
14. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 abrogates oncogene addiction and reduces liver metastasis in uveal melanoma. Zhang J; Liu S; Ye Q; Pan J Mol Cancer; 2019 Sep; 18(1):140. PubMed ID: 31526394 [TBL] [Abstract][Full Text] [Related]
15. Clinical Correlates of Response to Anti-PD-1-based Therapy in Patients With Metastatic Melanoma. Davis EJ; Perez MC; Ayoubi N; Zhao S; Ye F; Wang DY; Sosman JA; Al-Rohil RN; Eroglu Z; Johnson DB J Immunother; 2019; 42(6):221-227. PubMed ID: 30882548 [TBL] [Abstract][Full Text] [Related]
16. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292 [TBL] [Abstract][Full Text] [Related]
17. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Kottschade LA; McWilliams RR; Markovic SN; Block MS; Villasboas Bisneto J; Pham AQ; Esplin BL; Dronca RS Melanoma Res; 2016 Jun; 26(3):300-3. PubMed ID: 26848796 [TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254 [TBL] [Abstract][Full Text] [Related]
19. Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC. Tumeh PC; Hellmann MD; Hamid O; Tsai KK; Loo KL; Gubens MA; Rosenblum M; Harview CL; Taube JM; Handley N; Khurana N; Nosrati A; Krummel MF; Tucker A; Sosa EV; Sanchez PJ; Banayan N; Osorio JC; Nguyen-Kim DL; Chang J; Shintaku IP; Boasberg PD; Taylor EJ; Munster PN; Algazi AP; Chmielowski B; Dummer R; Grogan TR; Elashoff D; Hwang J; Goldinger SM; Garon EB; Pierce RH; Daud A Cancer Immunol Res; 2017 May; 5(5):417-424. PubMed ID: 28411193 [TBL] [Abstract][Full Text] [Related]
20. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ J Biol Chem; 2021; 296():100403. PubMed ID: 33577798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]